Abstract
Interleukin-26 (IL-26) is a member of the IL-10 cytokine family due to sequence homology. IL-26 was discovered, since the gene is strongly overexpressed in T cells which are growth transformed by herpesvirus saimiri. The IL-26 gene maps to human chromosome 12q15 between the genes for two other T-cellular class-II cytokines, namely interferon- λ (lFN-λ) and lL-22. IL-26, IL-22, and IFN-λ are co expressed by activated T cells and, especially, by Th17 cells. IL-26 forms homodimers and adheres to glycosaminoglycans on cell surfaces, presumably due to its positive charge. IL-26 specifically _targets the lL-26-specific heterodimeric receptor complex consisting of IL-20R1 and IL-10R2 which is typically expressed on epithelial cells such as colon carcinoma cells or keratinocytes. IL-26 stimulation induces STAT1 and STAT3 phosphorylation, CD54 surface expression, and cytokine secretion as shown for IL-8 and IL-10. IL-26 seems to act as a cell surface-associated and rather proinflammatory T-cell cytokine at the epithelial barrier, possibly linking T-cell response with epithelial functions.
Keywords: AK155, colon carcinoma, ICAM-1, Interleukin-26, IL-26, herpes virus saimiri, STAT, T cell, Th17
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title:Interleukin-26, a Highly Cationic T-Cell Cytokine _targeting Epithelial Cells
Volume: 11 Issue: 3
Author(s): Oliver Braum, Heide Pirzer and Helmut Fickenscher
Affiliation:
Keywords: AK155, colon carcinoma, ICAM-1, Interleukin-26, IL-26, herpes virus saimiri, STAT, T cell, Th17
Abstract: Interleukin-26 (IL-26) is a member of the IL-10 cytokine family due to sequence homology. IL-26 was discovered, since the gene is strongly overexpressed in T cells which are growth transformed by herpesvirus saimiri. The IL-26 gene maps to human chromosome 12q15 between the genes for two other T-cellular class-II cytokines, namely interferon- λ (lFN-λ) and lL-22. IL-26, IL-22, and IFN-λ are co expressed by activated T cells and, especially, by Th17 cells. IL-26 forms homodimers and adheres to glycosaminoglycans on cell surfaces, presumably due to its positive charge. IL-26 specifically _targets the lL-26-specific heterodimeric receptor complex consisting of IL-20R1 and IL-10R2 which is typically expressed on epithelial cells such as colon carcinoma cells or keratinocytes. IL-26 stimulation induces STAT1 and STAT3 phosphorylation, CD54 surface expression, and cytokine secretion as shown for IL-8 and IL-10. IL-26 seems to act as a cell surface-associated and rather proinflammatory T-cell cytokine at the epithelial barrier, possibly linking T-cell response with epithelial functions.
Export Options
About this article
Cite this article as:
Braum Oliver, Pirzer Heide and Fickenscher Helmut, Interleukin-26, a Highly Cationic T-Cell Cytokine _targeting Epithelial Cells, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2012; 11 (3) . https://dx.doi.org/10.2174/1871523011202030221
DOI https://dx.doi.org/10.2174/1871523011202030221 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Liver Stem Cells and Possible Clinical Applications
Current Stem Cell Research & Therapy Multiple Metamorphoses of CD38 from Prognostic Marker to Disease Modifier to Therapeutic _target in Chronic Lymphocytic Leukemia
Current Topics in Medicinal Chemistry Gene Therapy Approaches for Neuroprotection and Axonal Regeneration after Spinal Cord and Spinal Root Injury
Current Gene Therapy Are the Antioxidant Properties of Carvedilol Important for the Protection of Cardiac Mitochondria?
Current Vascular Pharmacology Immune Therapy of Multiple Sclerosis - Future Strategies
Current Pharmaceutical Design SRLVs: A Genetic Continuum of Lentiviral Species in Sheep and Goats with Cumulative Evidence of Cross Species Transmission
Current HIV Research Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid Leukemia
Anti-Cancer Agents in Medicinal Chemistry Iron Chelating Strategies in Systemic Metal Overload, Neurodegeneration and Cancer
Current Medicinal Chemistry Telomere Maintenance as Therapeutic _target in Embryonal Tumours
Anti-Cancer Agents in Medicinal Chemistry Molecular Foundations for Personalized Therapy in Prostate Cancer
Current Drug _targets Bortezomib and Arsenious Acid Synergistically Inhibit HL-60 Cells Viability in vitro and in vivo
Current Signal Transduction Therapy Potential and Cytotoxicity of cis-Platinum Complex with Anti-tumor Activity in Combination Therapy
Recent Patents on Anti-Cancer Drug Discovery Small Molecule Inhibition of the Bcl-XL-BH3 Protein-Protein Interaction: Proof-of-Concept of an In Vivo Chemopotentiator ABT-737
Current Topics in Medicinal Chemistry γ δ T Cell Modulation in Anticancer Treatment
Current Cancer Drug _targets Blocking Ca2+ Entry: A Way to Control Cell Proliferation
Current Medicinal Chemistry Regulatory Cross Talks of Bone Cells, Hematopoietic Stem Cells and the Nervous System Maintain Hematopoiesis
Inflammation & Allergy - Drug _targets (Discontinued) p73 as a Pharmaceutical _target for Cancer Therapy
Current Pharmaceutical Design The Role of the Oxysterol/EBI2 Pathway in the Immune and Central Nervous Systems
Current Drug _targets Recent Development in the Synthesis of Thiazoles
Current Organic Synthesis “Non-Taxifolin” Derived Flavonolignans: Phytochemistry and Biology
Current Pharmaceutical Design